NOV
52
-5
WU
24
4
TMO
42
-6
SBUX
37
-2
GD
41
-4
SRE
63
2
DLTR
38
-4
GE
61
-3
DVN
14
-6
INTU
58
-3
WAT
48
-11
NWS
75
-4
NEE
54
7
CAT
59
-2
EXR
57
2
NEM
40
3
EQR
54
3
ILMN
32
-9
WM
74
-5
CSCO
58
-2
NOV
52
-5
WU
24
4
TMO
42
-6
SBUX
37
-2
GD
41
-4
SRE
63
2
DLTR
38
-4
GE
61
-3
DVN
14
-6
INTU
58
-3
WAT
48
-11
NWS
75
-4
NEE
54
7
CAT
59
-2
EXR
57
2
NEM
40
3
EQR
54
3
ILMN
32
-9
WM
74
-5
CSCO
58
-2
Financhill
Back

Genetic Technologies 10K Form

Sell
27

GENE
Genetic Technologies

Last Price:
0.77
Seasonality Move:
29.34%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive GENE News And Ratings

See the #1 stock for the next 7 days that we like better than GENE

GENE Financial Statistics

Sales & Book Value

Annual Sales: $5.02M
Cash Flow: $0
Price / Cash Flow: 0
Annual Sales: $0.71
Price / Book: 0

Profitability

EPS (TTM): -0.60400
Net Income (TTM): $-4.08M
Gross Margin: $2.56M
Return on Equity: 0%
Return on Assets: 0%

Genetic Technologies Earnings Forecast

Key Genetic Technologies Financial Ratios

  • The Gross Profit Margin over the past 21 years for GENE is 50.94%.
  • The Selling, General & Administrative Expenses for GENE have been equal to 167.34% of Gross Profit Margin.
  • The Research & Development expenses have been 9.82% of Revenue.
  • The Interest Expense is -0.43% of Operating Income.
  • The Net Earning history of GENE is -156.78% of Total Revenues.
  • Per Share Earnings over the last 24 years have been positive in 15 years.

Genetic Technologies Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Life Sciences Tools & Services
Sector: Health Care
Current Symbol: GENE
CUSIP: 37185R
Website: gtglabs.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

GENE Technical Analysis vs Fundamental Analysis

Sell
27
Genetic Technologies (GENE) is a Sell

Is Genetic Technologies a Buy or a Sell?